Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Azetukalner by Xenon Pharmaceuticals for Major Depressive Disorder: Likelihood of Approval
Azetukalner is under clinical development by Xenon Pharmaceuticals and currently in Phase II for Major Depressive Disorder. According to GlobalData,...
Data Insights
Risk adjusted net present value: What is the current valuation of Xenon Pharmaceuticals's Azetukalner?
Azetukalner is a small molecule commercialized by Xenon Pharmaceuticals, with a leading Phase III program in Tonic-Clonic (Grand Mal) Seizure....